Venlo, the Netherlands, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes which can play a role in the diagnosis of Alzheimer's disease. This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping. The panel will be int ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senior ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net sha ...

QIAGEN N.V.'s (QGEN) growth is backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to macroeconomic volatilities and currency fluctuations, which can adversely affect its financial results. Year to date, this Zacks Rank #3 (Buy) stock has risen 0.9% compared with 10.5% growth of the industry. The S&P 500 composite has witnessed an 18.1% rise in ...

Company Overview - QIAGEN N.V. is a leading provider of technologies and products for the separation, purification, and handling of nucleic acids DNA/RNA, based in Venlo, the Netherlands [11] - The company offers over 500 proprietary, consumable products and automated solutions for sample collection, focusing on pre-analytical sample preparation and molecular diagnostics [11] Investment Ratings - QGEN currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B [12] - The stock has a Momentum Style Score of A, indicating strong upward price movement, with shares increasing by 12% over the past four weeks [12] Earnings Estimates - Seven analysts have revised their earnings estimates upwards for QGEN in the last 60 days for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.03 to $2.14 per share [12] - QGEN has an average earnings surprise of 2.6%, suggesting a positive outlook on earnings performance [12] Investment Consideration - With a solid Zacks Rank and high Momentum and VGM Style Scores, QGEN is recommended for investors' consideration [13]

QIAGEN N.V.'s (QGEN) second-quarter 2024 adjusted earnings per share (EPS) were 55 cents, the same at the constant exchange rate (CER). The reported figure increased 7.8% from the 2023 comparable figure and topped the Zacks Consensus Estimate by 5.8%. The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others. On a GAAP basis, the lo ...

Core Insights - Qiagen reported revenue of $496.35 million for the quarter ended June 2024, reflecting a year-over-year increase of 0.3% and surpassing the Zacks Consensus Estimate by 0.45% [1] - Earnings per share (EPS) for the quarter was $0.55, up from $0.53 in the same quarter last year, exceeding the consensus EPS estimate by 5.77% [1] Revenue Performance by Product Groups - Diagnostic solutions - QIAstat-Dx: Revenue of $24 million, a year-over-year increase of 14.3%, but below the average estimate of $24.37 million [3] - Diagnostic solutions - QuantiFERON: Revenue of $115 million, a year-over-year increase of 10.6%, exceeding the average estimate of $113.62 million [4] - Sample technologies: Revenue of $164 million, a year-over-year decrease of 0.6%, surpassing the average estimate of $160.34 million [5] - Diagnostic solutions: Revenue of $185 million, a year-over-year increase of 4.5%, closely matching the average estimate of $185.03 million [6] - Diagnostic solutions - NeuMoDx: Revenue of $7 million, a significant year-over-year decrease of 36.4%, falling short of the average estimate of $9.32 million [7] - Genomics / NGS: Revenue of $58 million, a year-over-year decrease of 9.4%, below the average estimate of $61.95 million [8] - PCR / Nucleic acid amplification: Revenue of $76 million, a year-over-year increase of 2.7%, exceeding the average estimate of $69.68 million [9] - Other: Revenue of $14 million, a year-over-year decrease of 6.7%, below the average estimate of $14.97 million [9] Revenue by Segment - Molecular Diagnostics: Revenue of $266 million, a year-over-year increase of 2.3%, surpassing the average estimate of $262.74 million [10] - Life Sciences: Revenue of $230 million, a year-over-year decrease of 2.1%, slightly below the average estimate of $231.79 million [11] - Diagnostic solutions - Other: Revenue of $39 million, a year-over-year decrease of 2.5%, exceeding the average estimate of $38.67 million [12] Stock Performance - Qiagen's shares have returned +9.9% over the past month, outperforming the Zacks S&P 500 composite, which saw a -0.4% change [12]

Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.77%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.44 per share when it actually produced earnings of $0.46, delivering a surprise of 4.55%. Over the last four quarters, the ...

Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supportin ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Qiagen (QGEN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estima ...